Business
Board appointment amendment
Board appointment amendment.
About this update from Hvivo Plc
[{"type":"text","content":"\n \n \n \n \n \n GENERAL TEXT AMENDMENT\n \n \n \n \n \n The following amendment has been made to the 'BOARD APPOINTMENT' announcement released on 8 June2022 at 07.00 under RNS No 0742O.\n \n \n \n \n \n An amendment has been made to the past directorships / partnerships adding\n Results International Group LLP\n \n \n All other details remain unchanged.\n \n \n \n \n \n The full amended text is shown below.\n \n \n \n \n \n \n Open Orphan plc\n \n \n \n \n (\"Open Orphan\" or the \"Company\")\n \n \n \n \n \n \n \n \n \n Board appointment\n \n \n \n \n \n \n \n Open Orphan plc\n \n \n \n (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials\n , announces the appointment of Martin Gouldstone as an Independent Non-Executive Director of the Company with effect from 8 June 2022.\n Martin will also Chair the Audit & Risk Committee and will be a member of the Nominations Committee and the Remuneration Committee.\n \n \n \n \n \n \n Martin brings 30 years of corporate development experience in the CRO, healthcare and pharmaceutical sectors, holding\n \n a number of senior roles at healthcare AI businesses. \n Martin has expertise in executing multi-billion dollar deals across Europe and the US, architecting end-to-end portfolio out-sourcing deals, and negotiating multi-year research partnerships.\n \n \n \n \n \n \n Martin is currently Global SVP, Business Development at Owkin, a French-American start-up using artificial intelligence to discover and develop better treatments for unmet medical needs. Previously, Martin has held the roles of Chief Business Officer at both BenevolentAI and Sensyne Health and was a Partner at Results Healthcare, an international M&A advisory firm, where he co-led the company's healthcare practice. Prior to this, Martin was Head of Life Sciences for BDO UK LLP, Senior Director responsible for M&A and joint venture opportunities in Europe for Quintiles (now IQVIA), and Business Development and Licensing Lead at Confirmant Ltd, Pharmacopeia Inc, Sareum Ltd.\n \n \n \n \n \n Martin holds a BSc in Genetics and has completed a range of post graduate management courses.\n \n \n &nb...